COVID-19 member update

We want to reassure you that we are taking the COVID-19 situation very seriously. The health and safety of our supporters, members, staff and the wider community is of utmost importance to us.

As such, we have taken decisive actions to support social distancing measures including cancelling face-to-face meetings and events, directing staff to work from home, and postponing Gutsy Challenge fundraising events.


Member Events:

  • The Joint Working Party Meeting scheduled for 15 May has been cancelled.
  • The Annual General Meeting scheduled for 15 May will go ahead with virtual participation encouraged via Zoom video conference.
  • The Idea Generation Workshop scheduled for 26 June has been postponed and, if possible, will be held later in 2020.
  • The 22nd Annual Scientific Meeting scheduled for 25-28 August will no longer be held as a face-to-face meeting. We are currently exploring options to hold this as a virtual meeting and will provide further updates in the coming weeks.


Gusty Challenge:

  • The Kakadu Gutsy Challenge scheduled for 16-22 August 2020 has been postponed to 8-14 August 2021.
  • The Treasure Road Gutsy Challenge scheduled for 28 September-2 October 2020 has been postponed to 20-24 September 2021.
  • The Mount Himlung Gutsy Challenge trek will now be held in 2021.


Innovation Fund update:

The AGITG Innovation Fund grant will still be awarded in 2020 however the opportunity will be limited to one grant of up to $200,000. The closing date for applications has been delayed to late 2020, date to be announced. The decision to limit grants this year has been made based on the considerable pressures many clinicians are under, and the need to focus on patient care first and foremost at this time. In the interest of public health, there is also the need to cancel key fundraising events and a likely impact on future fundraising appeals.


Clinical trial operations:

Where possible, trials are continuing to run as planned. We are working closely with Study Chairs, coordinating centres, and drug suppliers to minimise any potential impacts, and to ensure patient safety remains the top priority. Recruitment to open sites is proceeding, but on-site monitoring visits will be minimised. We acknowledge sites will face limitations and we will work with the AGITG Coordinating Centres to support sites in any way we can.


We appreciate your understanding and patience at this challenging time.

Russell Conley

Chief Executive Officer